# moderately to severely active ulcerative colitis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/moderately-to-severely-active-ulcerative-colitis

> 2 upcoming FDA catalysts in moderately to severely active ulcerative colitis: vedolizumab iv (TAK) on Sep to Dec 2027 (topline data readout); vedolizumab iv (TAK) on September 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 8, 2026 | [Entyvio® (vedolizumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/vedolizumab) | TAK | moderately to severely active ulcerative colitis | completed | "On 8 June 2026, the Company announced that the FDA had accepted for review a BLA for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326003974/exh_993.htm)) |
| Sep to Dec 2027 | [Vedolizumab iv topline data readout](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Moderately to Severely Active Ulcerative Colitis | scheduled | "NCT03221036 (Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03221036)) |
| September 2027 | [Vedolizumab iv primary completion](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Moderately to Severely Active Ulcerative Colitis | scheduled | "NCT03221036 (Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03221036)) |

## Drugs

- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/moderately-to-severely-active-ulcerative-colitis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "moderately to severely active ulcerative colitis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/moderately-to-severely-active-ulcerative-colitis

```bibtex
@misc{secapidev_indications_moderately_to_severely_active_ulcerative_colitis_20261116,
  title        = {moderately to severely active ulcerative colitis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/moderately-to-severely-active-ulcerative-colitis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_moderately_to_severely_active_ulcerative_colitis_20261116","title":"moderately to severely active ulcerative colitis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/moderately-to-severely-active-ulcerative-colitis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
